Revolutionary New Drug Offers 99.9% Protection Against HIV
While HIV prevention drugs, known as pre-exposure prophylaxis (PrEP), have existed for over a decade, their global impact has been limited due to the need for daily pill intake, a routine many struggle to follow consistently.
"This is a historic day in the decades-long fight against HIV. Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic," said Daniel O'Day, Chairman and Chief Executive Officer of Gilead Sciences. "This is a medicine that only needs to be given twice a year and has shown remarkable outcomes in clinical studies, which means it could transform HIV prevention. Gilead scientists have made it their life's work to end HIV, and now, with the FDA approval of Yeztugo and in collaboration with our many partners, we can help to make that goal a reality."
In 2024, Science hailed lenacapavir as its "Breakthrough of the Year".
Lenacapavir, marketed under the brand name Yeztugo, has been shown to reduce the risk of HIV transmission by more than 99.9 percent in adults and adolescents making it functionally akin to a powerful vaccine.
The company conducted two large clinical trials. The first, involving more than 2,000 women in sub-Saharan Africa, resulted in a 100 percent reduction in infections and demonstrated superiority over the daily oral pill Truvada.
In the second trial, involving over 2,000 men and gender-diverse individuals, only two infections were recorded - a 99.9 percent prevention rate, again surpassing Truvada.
Reported side effects included injection site reactions, headache, and nausea.
Results from both trials were published in The New England Journal of Medicine, and the journal Science named lenacapavir its 2024 "Breakthrough of the Year."
Pricing Raises Concerns Over Accessibility
Despite the impressive results, optimism may be tempered by the drug's expected high cost.
An earlier long-acting HIV prevention shot -- cabotegravir, which is injected every two months and was approved by the FDA in 2021 -- costs tens of thousands of dollars per year and has yet to make a major global impact.
While Gilead hasn't disclosed a price for Yeztugo, analysts estimate the US launch cost could reach $25,000 per year. Lenacapavir's current list price for its previously approved use as a treatment for HIV is $39,000 annually, though that is expected to drop when used as a preventive.
Activists are urging Gilead to drastically cut the price to help end the HIV pandemic.
"Even high-income countries will not be able to afford widescale use of lenacapavir at prices above US $20,000 per year," said Andrew Hill of Liverpool University, who led a team of chemists and scientists that found it could be mass-produced and sold for as little as $25 per person per year.
"To charge one thousand times more for a medicine with pandemic-ending potential would be abhorrent," added Winnie Byanyima, under-secretary-general of the United Nations. "We cannot end AIDS with medicines that are so costly."
The approval also comes as President Donald Trump's administration has slashed funding for HIV treatment and prevention programs both abroad and within the United States.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Is your rice toxic? Experts explain arsenic risks and how to stay safe
Rice is a kitchen staple in many homes, but it may not be as harmless as we think. A recent report has sparked worries, warning that rice sold in the United States contains dangerously high levels of inorganic arsenic, which is a toxic metal linked to cancer, heart disease, and impaired brain development in children. The report, published by Healthy Babies Bright Futures, a non-profit dedicated to reducing children's exposure to harmful chemicals, said that while the US and Italian rice are most toxic, Indian basmati and Thai jasmine rice are the safest choices. What is arsenic, and how does it get into our food? Arsenic is a naturally occurring toxic metal found in soil, water, and air. Rice is particularly effective at absorbing it because it is often grown in flooded fields where arsenic dissolves easily and is taken up by the roots. The report titled What's in your family's rice? found that all 145 rice samples sold across US supermarkets contained inorganic arsenic—the most harmful form. Some samples had arsenic levels up to 28 times higher than other grains like quinoa or millet. What are the health risks of eating arsenic-contaminated rice? According to Dr Tushar Tayal, Consultant, Internal Medicine, CK Birla Hospital, Gurugram, frequent exposure to arsenic, even in small amounts, can lead to serious health issues. Over time, it can damage the skin, stomach, nerves, and liver, and increase the risk of heart disease, diabetes, and lung or bladder cancer. Vulnerable groups at higher risk: There is no completely safe level of arsenic, especially inorganic arsenic, according to the World Health Organization and the US Food and Drug Administration. For drinking water, the limit is 10 parts per billion (ppb). In rice cereals for infants, the FDA allows a maximum of 100 ppb. Can cooking methods reduce arsenic in rice? How you cook your rice can make a difference. Dr Tayal and FDA guidelines recommend the following: Rinse rice thoroughly before cooking Cook in excess water (6 parts water to 1 part rice), then drain the extra water This method can reduce arsenic content by up to 50 per cent. What are safer alternatives to rice? If you are concerned about arsenic, nutritionists suggest varying your grains by adding: Quinoa Barley Oats Farro Millet These grains are lower in arsenic and offer similar health benefits. Arsenic is present in many foods and even in drinking water, so complete avoidance is not possible. The key, experts say, is to minimise exposure by eating a varied diet, choosing low-arsenic rice like Indian basmati, and using safer cooking methods.
Time of India
3 hours ago
- Time of India
Make cell and gene therapy more affordable: PSA tells experts
BENGALURU: As innovations in cell and gene therapies have taken root in India, Ajay K Sood, Principal Scientific Advisor, Govt of India, reminded scientists and innovators in Bengaluru, on Thursday, that efforts should be made to make these therapies affordable. The govt is also looking at a national mission that drives this affordability. Talking to experts at the India AMR innovation workshop at CCAMP in Bengaluru, Sood said, "Very often we see cell and gene therapies, which all of you are experts in, and if you look at the cost, that is really something which is not affordable in most countries — even in other developed countries. If you have to really make these therapies accessible, a large effort is needed. Innovations are taking place in isolated pockets, but the effort has to be amplified. " Sood, who also chairs the Prime Minister Science, Technology and Innovation Advisory Council, told TOI: 'Cell and gene therapy was discussed extensively in the recent meeting where we bring out various issues which have to be raised to the level of a mission. You Can Also Check: Bengaluru AQI | Weather in Bengaluru | Bank Holidays in Bengaluru | Public Holidays in Bengaluru We all felt it has to be a multi-ministerial effort, and we will need resources for that — it will be made into a mission — 'a cell and gene therapy mission'. The idea is how do we really make affordable cell and gene therapy products. While research is going on in a few labs and institutes, lots has to be done to take it to the market.' He added, 'First, you need the science and technology to make those molecules. After that, it has to be at scale to bring down the cost. One needs a holistic view that they are not only doing it for the country but for the globe. Both things have to go hand in hand.' 'We have to create a way to make our own chemicals. Unless we make that, we cannot reduce the cost. So that has to be, that is what is being done in this, at least in the IIT Bombay, and we will do in the mission,' he said. He added that therapy like 'ImmunoACT (the CAR-T cell therapy) is heavily supported by govt with initial funding from DBT, ICMR, and DST. How they take it to further reduce the cost is where all the private factors will come in, and they are already coming in.' Quantum Computing in drug discovery Meanwhile, Sood also believed that one can't avoid the use of quantum computing in biological sciences — "Billions of dollars are pouring in on drug discovery using quantum computing. That will be a game changer because all those huge permutation combinations will be so trivially done in quantum computing. This is really the future along with materials discovery and so on.' Antimicrobial resistance Talking about antimicrobial resistance being a prevalent issue, Ekroop Caur, Secretary, IT, BT, ST department, said, "Even though we may not take antibiotics or we may not misuse antibiotics, we are still affected by it — because what happens in the animal world and plant world will have an impact on us. This also calls for very strong pharmaceutical regulations, which is part of Karnataka's AMR action plan formulated in 2024." Taslimarif Saiyed, CEO and Director, CCAMP, pointed out the risk of nearly 10 million people dying annually from AMR — "I don't think one can step back and say we will look at it when it happens. I think collectively all of us are here to say how much I can take down from the 10 million.'
News18
3 hours ago
- News18
COVID-19 Vaccines and Heart Attacks: What You Really Need to Know
Last Updated: COVID-19 vaccines are overwhelmingly safe, with far lower heart risks than the infection itself. Recent reports of sudden cardiac deaths, particularly in Karnataka's Hassan district where 23 people died of heart attacks within 40 days, have stirred public concern over a possible link between COVID-19 vaccines and heart complications. However, health experts and investigations by ICMR and AIIMS have found no evidence directly connecting these heart attacks to the COVID-19 vaccine. According to Dr. Basavaraj Utagi, Senior Consultant Cardiologist, Fortis Hospital, 'COVID-19 infection itself carries a far greater risk of heart-related issues than the vaccine. Inflammation of the heart muscle, or myocarditis, is much more likely after infection than after vaccination." While global health agencies, including the U.S. FDA, have acknowledged rare cases of myocarditis particularly in young men following mRNA vaccines like Pfizer and Moderna, these incidents remain extremely uncommon. Most cases are mild and resolve with minimal treatment. As a precaution, the FDA has mandated updated labeling to reflect these risks, promoting transparency rather than alarm. Dr. Jeffrey Carstens, Cardiovascular Medical Director, UnityPoint Health, echoes this perspective: 'Yes, myocarditis after vaccination can happen, but it's very rare and generally not severe. On the other hand, COVID-19 infection can trigger dangerous inflammation that leads to heart attacks, arrhythmias, or heart failure." In fact, several studies show that COVID-19 vaccines may actually reduce the risk of heart attacks and strokes. A UK-based study found that vaccinated individuals had a lower incidence of arterial blockages, while Mount Sinai researchers observed fewer major cardiac events among vaccinated COVID patients. COVID-19 vaccines are overwhelmingly safe and remain a critical shield especially for older adults and those with existing health issues. The risk of severe heart problems is far greater from COVID infection than from the vaccine itself. If you experience symptoms like chest pain or shortness of breath post-vaccination, seek medical advice—but know that such cases are rare. In the debate between fear and fact, science continues to back the vaccine.
